Neurology · 3 h ago
Unified Movement Disorder Gene Panel Adds 0.4% Diagnostic Yield on Reanalysis
Researchers developed an evidence-tiered gene panel for movement disorders and tested targeted reanalysis in 4,046 previously undiagnosed clinical exomes. Reanalysis identified 16 diagnoses, increasing diagnostic yield by 0.4%.
- Panel includes 640 genes across three evidence tiers.
- Targeted reanalysis resolved 16 of 4,046 cases.
- Diagnostic yield increased by 0.4%.
- Many genes span multiple features and age groups.
The study developed a reproducible framework for a unified genetic panel for movement disorders (MDs), addressing variation in panel design across laboratories. Researchers assessed candidate genes using predefined inclusion and gene–disease validity criteria, assigning Green, Amber, or Red evidence tiers. Of 2,090 genes reviewed, 640 were selected: 537 Green, 36 Amber and 67 Red. The panel added 283 genes and removed 42 compared with the prior panel. The authors also assessed phenotype and age-at-onset data for Green genes.
The team then used a 220-gene list to reanalyse exomes from 4,046 previously undiagnosed MD cases. This identified 37 clinically relevant variants across 28 genes and resolved 16 cases, increasing diagnostic yield by 0.4%. The findings highlight substantial variation in phenotypic breadth and age at onset: only 17% of Green genes were associated with a single MD feature, and 43% were linked to both pediatric and adult presentations.
The results support the potential value of systematic panel curation and targeted reanalysis in undiagnosed cases. The reported yield increase was modest, and the abstract does not provide details on cohort characteristics or the clinical consequences of the diagnoses; broader applicability therefore remains uncertain.
In practice
For patients with movement disorders who remain undiagnosed after exome testing, targeted reanalysis using an updated, evidence-tiered gene set may identify additional diagnoses. In this cohort of 4,046 cases, reanalysis resolved 16 cases and increased diagnostic yield by 0.4%. This supports the potential value of periodic, systematic reanalysis, but the abstract does not specify cohort characteristics, timing of prior testing, or the clinical consequences of the diagnoses. The findings alone do not establish how often or when reanalysis should be performed.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Movement Disorders: Optimizing Genetic Analyses for Movement Disorders: A Unified Panel Approach and Targeted Reanalysis of 4,046 Clinical Exomes ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.